¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"tolerance to high altitude"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • low-dose tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • low-zone tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • maximum tolerance dose
    1. ÃÖ´ë³»¾à¿ë·®, ÃÖ´ë³»¾à·® 2. ÃÖ´ë°ßµõ¼±·®
  • median tolerance limit
    ¹Ý¼ö»ýÁ¸ÇѰè³óµµ
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´ç³»¼º°Ë»ç
  • organ tolerance dose
    ±â°ü°ßµõ¼±·®
  • oxygen tolerance
    »ê¼Ò³»¼º
  • self-tolerance
    1. ÀÚ°¡°ü¿ë 2. ÀÚ°¡³»¼º
  • high density lipoprotein
    °í¹ÐµµÁöÁú´Ü¹éÁú
  • high dose rate
    °í¼±·®·ü
  • high dose rate intraluminal radiotherapy
    °í¼±·®·ü°ü³»¹æ»ç¼±Ä¡·á
  • high energy bond
    °í¿¡³ÊÁö°áÇÕ
  • high energy compound
    °í¿¡³ÊÁöÈ­ÇÕ¹°
  • high energy phosphate compound
    °í¿¡³ÊÁöÀλ꿰ȭÇÕ¹°
  • high field magnetic resonance scanner
    °íÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maximum tolerance dose
    ÃÖ´ë³»¾à¿ë·®, ÃÖ´ë³»¾à·®, ÃÖ´ë°ßµõ¼±·®
  • organ tolerance dose
    ±â°ü°ßµõ¼±·®
  • tolerance dose
    °ßµõ¼±·®
  • exercise tolerance test
    ¿îµ¿³»¼º°Ë»ç
  • glucose insulin tolerance test
    Æ÷µµ´çÀν¶¸°°ßµõ°Ë»ç
  • glucose tolerance test
    Æ÷µµ´ç°ßµõ°Ë»ç
  • heat tolerance
    ³»¿­¼º
  • heparin tolerance test
    ÇìÆÄ¸°³»¼º°Ë»ç
  • immunologic tolerance
    ¸é¿ª°ü¿ë
  • induction tolerance
    ¸é¿ª°ü¿ëÀ¯¹ß
  • low-dose tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • low-zone tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • median tolerance limit
    ¹Ý¼ö»ýÁ¸ÇѰè³óµµ
  • metabolic tolerance
    ´ë»ç³»¼º
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´çºÎÇϰ˻ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acquired tolerance
    ÈÄõ(¼º) ³»¼º(¡­Ò±àõ), ȹµæ°ü¿ë.
  • acquired tolerance
    ȹµæ°ü¿ë, ÈÄõ¼º°ü¿ë
  • altimeter tolerance
    ³»°í¼Ò¼º(ËÀË­ËÛËÛ).
  • fructose tolerance test
    ÇÁ¶ôÅ佺ºÎÇϽÃÇè.
  • fructose tolerance test
    ÇÁ¶ôÅ佺ºÎÇϽÃÇè
  • galactose tolerance test
    °¥¶ôÅ佺ºÎÇÏ ½ÃÇè.
  • genetic tolerance dose
    À¯ÀüÀû ³»·®(¡­Ò±åÖ).
  • glucose insulin tolerance test =GITT
    Æ÷µµ´çÀν¶¸°ºÎÇϽÃÇè.
  • glucose tolerance
    ³»´ç·Â(Ò±ÓØæ³).
  • glucose tolerance test
    ´çºÎÇϽÃÇè
  • glucose tolerance test =GTT
    ´çºÎÇϰ˻ç(ÓØÝ¶ùÃËþÞÛ).
  • heat tolerance
    ³»¿­¼º(Ò±æðàõ).
  • heat tolerance
    ³»¿­¼º(ËÀËçËÛ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(¡­Ò±àõãËúÐ).
  • heparin protamin tolerance test
    ÇìÆÄ¸° ÇÁ·ÎŸ¹Î ³»¼º½ÃÇè(?ËÀËÛËàÌ´).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • alkali tolerance
    ¾ËÄ®¸®³»¼º(¡­Ò±àõ)
  • altimeter tolerance
    ³»°í¼Ò¼º(ËÀË­ËÛËÛ).
  • antigen tolerance
    Ç׿ø°ü¿ë.
  • autoimmune disease,immunologic tolerance
    ¸é¿ª°ü¿ë(Øóæ¹Î°é»)
  • autoimmune disease,tolerance
    ³»¿ë·Â(Ò®é»æ³)
  • carbohydrate tolerance
    ź¼öÈ­¹°ºÎÇÏ(¡­Ý¶ùÃ), ź¼öÈ­¹°³»Àμº.
  • carbohydrate tolerance test
    ź¼öÈ­¹°ºÎÇϽÃÇè.
  • cortisone glucose tolerance test =CGTT
    ÄÚ¸£Æ¼¼Õ Æ÷µµ´ç ºÎÇϽÃÇè(¡­øã Ô¬ÓØÝ¶ùÃãËúÐ).
  • cross tolerance
    ±³Â÷³»¼º(Îßó©Ò±àõ)
  • cross tolerance
    ±³Â÷¸é¿ª°ü¿ë
  • cross-tolerance
    ±³Â÷³»¼º(Îßó©Ò±àõ)
  • diabetes mellitus,oral glucose tolerance test
    °æ±¸´çºÎÇÏ °Ë»ç(ÌèÏ¢ÓØÝ¶ùà ËþÞÛ)
  • drug disposition tolerance
    ¾à¹°ºÐÇØ³»¼º.
  • drug tolerance
    ¾à¹°<¾àÁ¦>³»¼º.
  • drug tolerance
    ¾à¹°³»¼º(å·ÚªÒ±àõ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-density lipoprotein
    °í¹Ðµµ ÁöÁú´Ü¹éÁú(ÍÔÚËÓøò·òõÓ±ÛÜòõ)
  • high-energy bond
    °í(ÍÔ)¿¡³ÊÁö °áÇÕ(Ì¿ùê)
  • high-energy compound
    °í(ÍÔ)¿¡³ÊÁö È­ÇÕ¹°(ûùùêÚª)
  • high-energy ion scattering
    °í(ÍÔ)¿¡³ÊÁö À̿»ê¶õ(ߤկ)
  • high-energy phosphate donor
    °í(ÍÔ)¿¡³ÊÁö ÀÎ»ê°ø¿©ÀÚ(×òß«Íêæ¨í­)
  • high-level promoter
    °íÀ§(ÍÔêÈ)ÇÁ·Î¸ðÅÍ
  • high-lipid lipoprotein
    °íÁöÁú ÁöÁú´Ü¹éÁú(ÍÔò·òõò¢òõÓ±ÛÜòõ)
  • high-mannose glycoproteins
    ´Ù(Òý)¸¸³ë½º ´ç´Ü¹éÁú(ÓØÓ±ÛÜòõ)
  • high-mannose oligosaccharides
    ´Ù(Òý)¸¸³ë½º °ú´çÁú(ÍûÓØòõ)
  • high-mobility group
    °íÀ̵¿µµ ±º(ÍÔì¹ÔÑÓøÏØ)
  • high-performance liquid chromatography
    °í¼º´É(ÍÔàõÒö) ¾×ü(äûô÷) Å©·Î¸¶Åä±×·¡ÇÇ
  • high-potential iron protein
    °íÀüÀ§(ÍÔï³êÈ) ö´Ü¹éÁú(ôÑÓ±ÛÜòõ)
  • high-pressure liquid chromatography
    °í¾Ð(ÍÔäâ) ¾×ü(äûô÷)Å©·Î¸¶Åä±×·¡ÇÇ
  • high-quality proteins
    °í±Þ ´Ü¹éÁú(ÍÔÐäÓ±ÛÜòõ)
  • high-speed sedimentation equilibrium
    "°í¼Ó ħ°­ÆòÇü(ÍÔáÜöØË½øÁû¬)(¹ý,Ûö)"
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high resolution computed tomography [=HRCT]
    °íÇØ»óÀü»êÈ­´ÜÃþÃÔ¿µ¼ú
  • high risk group
    °íÀ§Çèµµ±º
  • high signal
    °í½ÅÈ£
  • high signal intensity
    °í½ÅÈ£°­µµ
  • high spatial frequency algorithm
    °í°ø°£Á֯ļö¿¬»ê
  • high speed
    °í¼ÓÀÇ
  • high speed core cut biopsy
    °í¼ÓÁ߽ɻý°Ë
  • high velocity signal loss
    °í¼Óµµ½ÅÈ£¼Ò½Ç
  • high voltage radiography
    °í¾ÐÃÔ¿µ¼ú
  • high voltage radiography
    °íÀü¾ÐÃÔ¿µ¼ú
  • HRCT [=high resolution comnputed tomography]
    °íÇØ»óÀü»êÈ­´ÜÃþÃÔ¿µ¼ú
  • paramagnetic high susceptibility
    »óÀÚ¼º°íÀÚÈ­À²
  • pseudodiastole in high intensity proton flow
    °í°­µµ¾çÀÚÀ¯µ¿¿¡¼­ À§À̿ϱâ
  • super high field MR scanner
    ÃʰíÀÚÀåMR½ºÄ³³Ê, ÃʰíÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
  • ultra high field MR scanner
    ÃʰíÀÚÀåÀÚ±â°ø¸í½ºÄ³³Ê
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HAP Handicapped Aid Program; Hazardous Air Pollutants [List]; hazardous air pollution; health alliance p...
HAPE high-altitude pulmonary edema
HAR high-altitude retinopathy
HARH high-altitude retinal hemorrhage
HHCS high-altitude hypertrophic cardiomyopathy syndrome
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FTQ Fagerstrom Tolerance Questionnaire
FSIGTT Frequently sampled intravenous glucose tolerance test
GTF Glucose Tolerance Factor
75 g Glucose Tolerance Test
GTT Glucose Tolerance Test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
  • median tolerance limit
    ¹Ý¼ö »ýÁ¸ ÇÑ°è ³óµµ
  • organ tolerance dose
    ±â°ü Çã¿ë·®, Àå±â Çã¿ë·®
  • pain tolerance
    µ¿Åë ³»¼º, ÅëÁõ ³»¼º
    ÂüÀ» ¼ö ÀÖ´Â ÅëÁõÀÇ °¡Àå Å« ¼öÁØ.
  • pharmacodynamic tolerance
    ¾à¿ªÇÐÀû ³»¼º
  • poison tolerance
    µ¶¹° ³»¼º
    Áö¼ÓÀûÀÎ µ¶¼º ¹°Áú¿¡ ÀÇÇØ »ýü°¡ ±× µ¶¼º ¹°Áú¿¡ ÀúÇ×¼ºÀ» ³ªÅ¸³»´Â °Í.
  • tolerance
    ³»¾à¼º, ³»¼º, ³»¿ë·Â, Çã¿ë, °ü¿ë
    1. º¸Åë ¾à¹°À̳ª µ¶¹°ÀÇ ¸¹Àº »ç¿ë·®À» °ßµð¾î ³¾ ¼ö ÀÖ´Â ´É·Â. 2. ÈÄõÀûÀ¸·Î ȹµæµÈ ¾à¹° ³»¼º. ¹Ýº¹ÀûÀÎ µ¿·®ÀÇ »ç¿ë·®¿¡ ´ëÇÑ ¹ÝÀÀ¼ºÀÇ °¨¼Ò ȤÀº °°Àº ¹ÝÀÀÀ» ¾ò±â À§Çؼ­ Áõ°¡µÈ »ç¿ë·®À» ¿ä±¸ÇÏ´Â °Í.
  • tolerance span
    Àγ» ±â°£
  • tolerance to antimicrobial
    Ç×±ÕÁ¦ ³»¼º
  • admixed high-copper alloy
    È¥ÇÕÇü °íµ¿ÇÕ±Ý
    °íµ¿ÇÕ±ÝÀÇ °¡Àå ¿À·¡µÈ ÇüÅ·μ­ Àº, ÁÖ¼®, 6% ÀÌÇÏÀÇ ±¸¸®¸¦ ÇÔÀ¯ÇÑ Àç·¡Çü Àúµ¿ÇԱݰú ´ë°Ô ±¸¸®°¡ ¸¹Àº Àº-±¸¸® °øÁ¤ ÇÕ±ÝÀÇ µÎ °¡Áö ºÐ¸»À» È¥ÇÕÇÏ¿© ±¸¸®ÀÇ ÃÑ·®À» Áõ°¡½ÃŲ °ÍÀÌ´Ù. Àúµ¿ Àç·¡Çü ÇÕ±ÝÀº Àý»èÇüÀÌ¸ç °íµ¿ÇÕ±ÝÀº ±¸»óÇüÀ̾ °á°úÀûÀ¸·Î Àý»èÇü°ú ±¸»óÇüÀÌ È¥ÇÕµÈ °ÍÀÌ´Ù.
  • high arched
    ³ôÀº ±¸°³±Ã
  • high cellular component
    °í¼¼Æ÷ ±¸¼º ¼ººÐ
  • high condylectomy
    °í °úµÎ ÀýÁ¦¼ú, »ó°úµÎ ÀýÁ¦¼ú
    »ó,ÇÏ¾Ç °úµÎÀÇ ÀϺκи¸À» ¿Ü°úÀûÀ¸·Î Á¦°ÅÇÏ´Â °Í.
  • high copper amalgam
    °íµ¿ ¾Æ¸»°¨
    ¾Æ¸»°¨ Çձݿ¡¼­ ±¸¸®ÀÇ ºñ°¡ ³ôÀº °Í.
  • high electron density
    °íÀüÀÚ ¹Ðµµ
    ÀüÀÚµéÀÇ ¹Ðµµ°¡ ³ôÀº °÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
pain tolerance The greatest intensity of painful stimulation that an individual is able to tolerate.
(05 Mar 2000)
gamma-tolerance The tolerance of a person or a piece of equipment to forces that develop as a result of acceleration or deceleration.
(05 Mar 2000)
vibration tolerance The maximum vibratory or oscillatory movements that an individual can experience and bear without pain; the limit of tolerance is a function of amplitude and frequency of the vibration and varies with the direction of application.
(05 Mar 2000)
glucose tolerance factor A water-soluble complex containing chromium needed for normal glucose tolerance.
(05 Mar 2000)
glucose tolerance test <chemical pathology, investigation> A special test where the blood glucose is measure in intervals after a glucose-rich meal is taken, a test used for diagnosing diabetes.
(27 Sep 1997)
work schedule tolerance Physiological or psychological effects of periods of work which may be fixed or flexible such as flexitime, work shifts, and rotating shifts.
(12 Dec 1998)
cross tolerance <pharmacology> The resistance to one or several effects of a compound as a result of tolerance developed to a pharmacologically similar compound.
(05 Mar 2000)
xylose tolerance test <investigation> This test measures the intestine's ability to absorb the simple sugar, D-xylose.
This is an indicator for whether or not nutrients are being absorbed properly in the intestine. This test is often used to evaluate persistent diarrhoea, weight loss, malnutrition and cases of suspected malabsorption.
Abnormal results may be seen in the following conditions: Crohn's disease, Giardiasis, hookworm infestation, radiation enteritis, celiac sprue, viral gastroenteritis and Whipple's disease.
(27 Sep 1997)
self tolerance The normal lack of the ability to produce an immunological response to autologous (self) antigens. A breakdown of self tolerance leads to autoimmune diseases. The ability to recognise the difference between self and non-self is the prime function of the immune system.
(12 Dec 1998)
species tolerance The insensitivity to a particular drug exhibited by a particular species.
(05 Mar 2000)
split tolerance Modification of an immune response to an antigen after prior exposure to that antigen.
Synonym: split tolerance.
(05 Mar 2000)
nonresponder tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
drug tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein a human, animal, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug.
(12 Dec 1998)
immune tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (foetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
(12 Dec 1998)
immunological tolerance <immunology> Specific unresponsiveness to antigen. Self tolerance is a process occurring normally early in life due to suppression of self reactive lymphocyte clones.
Tolerance to foreign antigens can be induced in adult life by exposure to antigens under conditions in which specific clones are suppressed. Note that tolerance is not the same as immunological unresponsiveness, since the latter may be very non-specific as in immunodeficiency states.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • high-coloured
    ¼±¸íÇÑ »öÁ¶
  • high-muck-a-muck
    ³ôÀº »ç¶÷
  • high-muckety-muck
    ³ôÀº »ç¶÷
  • high-spirited
    ±â¿îÂù
  • high-tone
    °¡¶ôÀÌ ³ôÀº
  • high-toned
    °¡¶ôÀÌ ³ôÀº
  • High Dutch
    =High German
  • High Street
    Å«(¹øÈ­ÇÑ) °Å¸®
  • Lord High Chancellor
    ´ë¹ý°ü
  • Middle High German
    Áß¼¼(Áß±â) °íÁö µ¶ÀϾî(12-15¼¼±â)
  • Old High German
    =GERMAN
  • contact high
    °¨¿°(°£Á¢) µµÃë(¸¶¾àµµÃëÀÚ¿Í Á¢Çϰųª ¿¬±â³¿»õ·Î ÃëÇϱâ)
  • extremely high frequency
    (Åë½Å)ÃʰíÁÖÆÄ
  • high
    ³ôÀº;...ÀÇ ³ôÀÌÀÇ;³ôÀº °÷(À¸·ÎºÎÅÍ)ÀÇ;°íÁöÀÇ;°í±Í(°í»ó,¼þ°í)ÇÑ;°í¿øÀÇ;°íÀ§ÀÇ;°í±ÞÀÇ;°ªºñ½Ñ;°Ý·ÄÇÑ;±ØµµÀÇ;°ú°ÝÇÑ;£Àº
  • high
    (¿¬°áÇü)(~³ôÀÌÀÇ)ÀÇ ¶æ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á